BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Fuse Science and Macular Health Advance Commercial Formula Into Clinical Study for AMD Sufferers


1/15/2013 10:09:18 AM

MIAMI LAKES, Fla., Jan. 15, 2013 /PRNewswire/ -- Fuse Science Inc. (OTCQB: DROP), (www.fusescience.com), an innovative consumer products and delivery technology company that is developing new, patent-pending technologies poised to redefine how consumers receive energy, medicines, vitamins and minerals, announced today that in furtherance of its planned licensing relationship with Macular Health, LLC, Fuse Science has developed a DROP formulation of Macular Health's macular degeneration nutritional supplement (currently marketed in capsule form) for immediate clinical studies in conjunction with Macular Health. Macular Health (www.macularhealth.com) is one of the leading manufacturers of macular degeneration nutritional supplements. This study will hopefully further validate the efficacy of Fuse Science's DROP delivery technology for the treatment of Age-Related Macular Degeneration ("AMD").

There is no known cure for AMD, which is the leading cause of blindness in adults. Each year 1.2 million of the estimated 12 million people afflicted with AMD will suffer severe central vision loss. AMD is caused by the breakdown of the macula of the eye, which typically occurs during the aging process.

The clinical study will follow the same Multifocal Electroretinogram ("MERG") protocol that Macular Health used at the UAB Callahan Eye Foundation Hospital in Birmingham, Alabama, by John O. Mason, III. , M.D., using their capsule formula. MERG researchers reported that the study established benefits for people taking Macular Health's capsule formulation, with an average of 16 percent improvement in retina function in only 12 weeks and 17 percent improvement in retina function after two years of taking the Macular Health supplement. While there is no known cure for AMD, Macular Health's formulation is proven to help AMD sufferers slow the progression of vision loss. The objective of this Fuse Science partnership is to improve upon these results through a DROP formulation of Macular Health's nutritional supplement.

"The goal for Macular Health is to continue to advance the benefits to AMD sufferers from taking macular degeneration nutritional supplements, thereby potentially slowing the progression of vision loss," said Macular Health's President, Jeffery McAnnally. "We believe that Fuse Science's DROP delivery technology has the potential to improve patient compliance and improve overall outcomes as it's applied to current and future products."

The study will enroll AMD sufferers and evaluate the treatment of using a supplement therapy DROP, instead of a pill or capsule. A MERG will be given to patients prior to starting the therapy, then a repeat MERG will be given 12 weeks after completion of treatment. The MERG test is absolutely objective so there is no chance of a placebo effect. The study is being done at the UAB Callahan Eye Foundation Hospital by Dr. John O. Mason III, M.D.

"Our Company continues to make real strides in the application of our technology and Macular Health represents one of the first planned licensing efforts of our delivery system," said Jeanne Hebert, Vice President Marketing and Clinical Research. "We have been able to successfully integrate the Macular Health formula into our DROP technology in under five months. This showcases our speed to market and our team's ability to react in real time. We anticipate many licensing relationships being established as part of our current licensing and M&A effort firmly under way, facilitated by Atlas Advisors."

About Macular Health
Macular Health (www.macularhealth.com) is the leading manufacturer of nutritional supplements for people suffering from macular degeneration, the leading cause of blindness in the United States. Macular Health formulations are scientifically based on the AREDS formula and market a line of Macular Degeneration supplement therapies. These supplement therapies have demonstrated their proven efficacy in reducing vision loss of AMD sufferers.

About Fuse Science Inc.
Fuse Science Inc. (OTCQB: DROP), is an innovative consumer products holdings and delivery technology company based in Miami Lakes, Florida. Fuse Science holds the rights to new, patent-pending technologies poised to redefine how consumers receive energy, medicines, vitamins and minerals. The Company maintains the rights to sublingual and transdermal delivery systems for bioactive agents that can now, for the first time, effectively encapsulate and charge many varying molecules in order to produce complete product formulations which can bypass the gastrointestinal tract and enter the blood stream directly - all in a concentrated "DROP" form that is simply applied under the tongue. The Fuse Science technology is designed to accelerate conveyance of medicines or nutrients relative to traditional pills and liquids and can enhance how consumers receive these products. Information about Fuse Science is available online at www.fusescience.com and www.poweredbyfuse.com or by calling 305-503-FUSE (3873).

For more information:

To schedule an interview:

Fuse Science, Inc.

Gus DeQuesada

Investor Relations

Michelsen Advertising

Direct: (305) 503-3873, Ext. 2

C-305-733-1410 / 786-488-7138

Email: ir@fusescience.com

prnews@michelsenadvertising.com

Safe Harbor Statement
Certain statements and information included in this release may constitute "forward-looking statements" as defined in the Federal Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied in such statements. Additional discussion of factors that could cause actual results to differ materially from management's projections, estimates and expectations is contained in the Company's SEC filings. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by federal securities laws.

SOURCE Fuse Science Inc.



Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->